Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

HCW9218

Fusion protein · Immune activation, directed at TGF-beta · developed by ImmunityBio

Phase 1/2 Most advanced trial (none active)

IBRX Developer

1 Registered trials

What is HCW9218?

HCW9218 is a bifunctional fusion protein combining the ectodomain of TGF-beta receptor II with an IL-15/IL-15 receptor alpha complex. It neutralizes TGF-beta to reduce immunosuppression in the tumor microenvironment while stimulating NK cell and T-cell proliferation and cytotoxic activity. It is being studied in advanced pancreatic carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Fusion protein
Targets: TGF-beta
Mechanism: Immune activation, directed at TGF-beta
Pathways: TGF-beta signaling, NK cell activation, T-cell proliferation
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05304936	Phase 1/2	Advanced Pancreatic Carcinoma	Completed	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Pancreatic Carcinoma

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind HCW9218

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z